185 related articles for article (PubMed ID: 34331012)
1. MASTL regulates EGFR signaling to impact pancreatic cancer progression.
Fatima I; Barman S; Uppada J; Chauhan S; Rauth S; Rachagani S; Ponnusamy MP; Smith L; Talmon G; Singh AB; Batra SK; Dhawan P
Oncogene; 2021 Sep; 40(38):5691-5704. PubMed ID: 34331012
[TBL] [Abstract][Full Text] [Related]
2. MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling.
Uppada SB; Gowrikumar S; Ahmad R; Kumar B; Szeglin B; Chen X; Smith JJ; Batra SK; Singh AB; Dhawan P
Mol Cancer; 2018 Aug; 17(1):111. PubMed ID: 30068336
[TBL] [Abstract][Full Text] [Related]
3. MASTL: A novel therapeutic target for Cancer Malignancy.
Fatima I; Singh AB; Dhawan P
Cancer Med; 2020 Sep; 9(17):6322-6329. PubMed ID: 32692487
[TBL] [Abstract][Full Text] [Related]
4. Mastl kinase, a promising therapeutic target, promotes cancer recurrence.
Wang L; Luong VQ; Giannini PJ; Peng A
Oncotarget; 2014 Nov; 5(22):11479-89. PubMed ID: 25373736
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Microtubule Associated Serine/threonine Kinase Like Expression Inhibits Gastric Cancer Cell Growth and Induces Apoptosis by Activation of ERK1/2 and Inactivation of NF-κB Signaling.
An CX; Xie SP; Li HL; Hu YH; Niu R; Zhang LJ; Jiang Y; Li Q; Zhou YN
Curr Med Sci; 2021 Feb; 41(1):108-117. PubMed ID: 33582914
[TBL] [Abstract][Full Text] [Related]
6. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
Ricciardiello F; Gang Y; Palorini R; Li Q; Giampà M; Zhao F; You L; La Ferla B; De Vitto H; Guan W; Gu J; Zhang T; Zhao Y; Chiaradonna F
Oncogene; 2020 May; 39(20):4103-4117. PubMed ID: 32235891
[TBL] [Abstract][Full Text] [Related]
7. MASTL promotes cell contractility and motility through kinase-independent signaling.
Taskinen ME; Närvä E; Conway JRW; Hinojosa LS; Lilla S; Mai A; De Franceschi N; Elo LL; Grosse R; Zanivan S; Norman JC; Ivaska J
J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32311005
[TBL] [Abstract][Full Text] [Related]
8. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.
Tian J; Lin Y; Yu J
Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.
Kaushik G; Seshacharyulu P; Rauth S; Nallasamy P; Rachagani S; Nimmakayala RK; Vengoji R; Mallya K; Chirravuri-Venkata R; Singh AB; Foster JM; Ly QP; Smith LM; Lele SM; Malafa MP; Jain M; Ponnusamy MP; Batra SK
Oncogene; 2021 Jan; 40(4):848-862. PubMed ID: 33288882
[TBL] [Abstract][Full Text] [Related]
10. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.
Álvarez-Fernández M; Sanz-Flores M; Sanz-Castillo B; Salazar-Roa M; Partida D; Zapatero-Solana E; Ali HR; Manchado E; Lowe S; VanArsdale T; Shields D; Caldas C; Quintela-Fandino M; Malumbres M
Cell Death Differ; 2018 May; 25(5):828-840. PubMed ID: 29229993
[TBL] [Abstract][Full Text] [Related]
12. Kinase-Independent Functions of MASTL in Cancer: A New Perspective on MASTL Targeting.
Conway JRW; Närvä E; Taskinen ME; Ivaska J
Cells; 2020 Jul; 9(7):. PubMed ID: 32640605
[TBL] [Abstract][Full Text] [Related]
13. Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.
Dahlhaus M; Burkovski A; Hertwig F; Mussel C; Volland R; Fischer M; Debatin KM; Kestler HA; Beltinger C
Cancer Lett; 2016 Feb; 371(1):79-89. PubMed ID: 26616283
[TBL] [Abstract][Full Text] [Related]
14. AKT Regulates Mitotic Progression of Mammalian Cells by Phosphorylating MASTL, Leading to Protein Phosphatase 2A Inactivation.
Reshi I; Nisa MU; Farooq U; Gillani SQ; Bhat SA; Sarwar Z; Nabi N; Fazili KM; Andrabi S
Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123010
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
[TBL] [Abstract][Full Text] [Related]
16. MASTL overexpression promotes chromosome instability and metastasis in breast cancer.
Rogers S; McCloy RA; Parker BL; Gallego-Ortega D; Law AMK; Chin VT; Conway JRW; Fey D; Millar EKA; O'Toole S; Deng N; Swarbrick A; Chastain PD; Cesare AJ; Timpson P; Caldon CE; Croucher DR; James DE; Watkins DN; Burgess A
Oncogene; 2018 Aug; 37(33):4518-4533. PubMed ID: 29743597
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
19. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV
Br J Cancer; 2020 May; 122(10):1486-1495. PubMed ID: 32203220
[TBL] [Abstract][Full Text] [Related]
20. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
